Val-ILs loaded with an antibody against CD33, at a dose of 4000 particles per cell, also demonstrated efficient alterations in the viability of two acute myeloid leukemia (AML) cell lines, HL60 (68% decrease, P < 0.0001) and THP1 (100% decrease, P < 0.0001, Fig. 4B). This evidence concerns the gene CD33 and acute myeloid leukemia.